ISMRC2011 encourages abstract submission for Oral Presentation and Poster Presentation.
Step 1:
Complete your registration to the Conference and get your Registration ID. To register to ISMRC2011, please click here.
Step 2:
Access the on-line abstract submission page and submit you£ò abstract. Your Registration ID is needed to complete your submission.
Step 3:
You will receive the automatic notice of abstract receipt.
| Deadline for Abstract Submission | June 10, 2011 |
|---|---|
| Notice of Abstract Acceptance | By the end of June, 2011 |
| Deadline for Early Registration | July 25, 2011 |
| Deadline for Full Refund | June 30, 2011 |
¢¨Please note that the registration is incomplete without payment.
Submitted abstracts will be reviewed by the Program Committee, and the accepted abstract will be announced to the author by E-mail. The announcement will be made by the end of June, 2011.
| 1. | Cancer associated factors (CAF) |
|---|---|
| 2. | Cancer stem cells |
| 3. | Chromosomal rearrangement |
| 4. | Clinical significance of CTCs and DTCs |
| 5. | Cytokines and chemokines |
| 6. | Epigenetic factors |
| 7. | Epithelial mesenchymal transition (EMT) and MET |
| 8. | Genetic factors (SNP) |
| 9. | Inflammation |
| 10. | iPS |
| 11. | Lymphangiogenesis |
| 12. | Microvesicles |
| 13. | Molecular target therapy |
| 14. | Nano-technologies |
| 15. | Neo-vascularization |
| 16. | Niche |
| 17. | Non-coding RNA, MicroRNA |
| 18. | Novel Technologies for CTCs and DTCs |
| 19. | Prevention of cancer metastasis |
| 20. | Proteinase and MMPs |
| 21. | Telomere |
| 22. | TGF-beta |
| 23. | Tumor Immunology |
| 24. | Tumor markers |
| 25. | Vaccines |
| 26. | Others |
The title of the presentation should be less than 100 one-byte characters.
The text of the abstract should be less than 2,700 one-byte characters.
- 1. Abstract submitted via the website can be revised online until June 10, 2011.
- 2. Any corrections to be made to your abstract will be your own responsibility.
- 3. If you find correction via the website to be difficult, please contact the secretariat with your abstract ID, which will be issued after the submission of your abstract, as well as the name of the presenting author of your abstract.
The contents of submitted abstract should be approved by their institutions' ethical committee.
Presentation is to be made in either podium or poster session. When you submit your abstract, you may choose which type of presentation you would like to make. Please note that we may ask you to change the style of presentation, if necessary, as a result of examination of your abstract.
- ¢£ Convention Linkage, Inc.
- PIAS TOWER 11F, 3-19-3 Toyosaki, Kita-ku, Osaka 531-0072, Japan
TEL: +81-6-6377-2188 FAX: +81-6-6377-2075
E-mail: ismrc2011@secretariat.ne.jp